In order to understand the wider relevance of this finding, we interrogated a publicly available dataset (Grasso et al. 2012) and found LXN mRNA levels to be significantly downregulated in metastatic prostate cancer specimens when compared to normal prostate tissue (Fig. 1G)23,24. The gene discussed is LXN; the disease is prostate carcinoma.